Quick Answer
TELA Bio, Inc. reported Operating Income Loss of -$33.76 million for the year ending 2025.
- TELA Bio, Inc. showed an increase of +1.1% in Operating Income Loss from 2024 to 2025.
- This data is from TELA Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), TELA Bio, Inc.'s Operating Income Loss has declined by 99.5%.
- Historical annual values: Fiscal year 2025: -$33.76 million | Fiscal year 2024: -$34.12 million | Fiscal year 2023: -$44.08 million | Fiscal year 2022: -$39.01 million | Fiscal year 2021: -$29.45 million | Fiscal year 2020: -$25.28 million | Fiscal year 2019: -$19.16 million | Fiscal year 2018: -$17.78 million | Fiscal year 2017: -$16.92 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: